Clinical Trials Logo

Follicular Lymphoma (FL) clinical trials

View clinical trials related to Follicular Lymphoma (FL).

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04830137 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Start date: May 5, 2021
Phase: Phase 1
Study type: Interventional

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.

NCT ID: NCT04450069 Active, not recruiting - Clinical trials for Mantle Cell Lymphoma

CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies

Start date: August 14, 2020
Phase: Phase 1
Study type: Interventional

CLBR001 + SWI019 is an combination investigational immunotherapy being evaluated as a potential treatment for patients diagnosed with B cell malignancies who are refractory or unresponsive to salvage therapy or who cannot be considered for or have progressed after autologous hematopoietic cell transplantation. This first-in-human study will assess the safety and tolerability of CLBR001 + SWI019 and is designed to determine the maximum tolerated dose (MTD) or optimal SWI019 dose (OSD). Patients will be administered a single infusion of CLBR001 cells followed by cycles of SWI019. The study will also assess the pharmacokinetics and pharmacodynamics of CLBR001 + SWI019.

NCT ID: NCT04049513 Active, not recruiting - Clinical trials for Diffuse Large B-cell Lymphoma (DLBCL)

ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)

ENABLE
Start date: October 11, 2019
Phase: Phase 1
Study type: Interventional

This Phase 1, single centre, open label dose escalation study aims to identify a safe dose of third-generation anti-CD19 CAR T-cells (WZTL-002) in the treatment of patients with relapsed or refractory (r/r) B-cell Non Hodgkin Lymphoma, for use in further efficacy trials. An expansion cohort will assess automated closed-system manufacture of WZTL-002 and outpatient management of participants.

NCT ID: NCT02362035 Active, not recruiting - Multiple Myeloma Clinical Trials

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

KEYNOTE145
Start date: February 20, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.